Ergoteles’s Procept Biorobotics PRCT Stock Holding History

Ergoteles’s Portfolio PRCT Stock Details PRCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10,755	Closed	-$376K	–	1925
2022 Q1	$376K	Buy	+10,755	New	+$259K	0.01%	772

Other funds holding PRCT

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

FRA

Frank Rimerman Advisors Palo Alto, California $1.53B AUM 30.5% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Ergoteles's PRCT Position: Q2 2022 in Review

Ergoteles sold out of Procept Biorobotics (PRCT) in Q2 2022, closing a stake of 10,755 shares — an estimated $376K sold.

Ergoteles first reported a position in PRCT in Q1 2022 and held it in 1 quarter. The position peaked at $376K in Q1 2022. 96 funds tracked by Wall St. Rank hold PRCT as of Q2 2022.

Ergoteles reported no remaining Procept Biorobotics position as of Q2 2022 after selling out during the quarter.
Ergoteles sold 10,755 Procept Biorobotics shares in Q2 2022, an estimated $376K.
Ergoteles first reported a position in Procept Biorobotics in Q1 2022 and held it in 1 quarter.
Ergoteles's Procept Biorobotics position peaked at $376K in Q1 2022.
96 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2022.

Based on Ergoteles's 13F filing for Q2 2022, filed 12 Aug 2022.